Clinical Research Directory
Browse clinical research sites, groups, and studies.
GnRH for Luteal Support - Mechanism of Action
Sponsor: Heli Alexandroni
Summary
This prospective observational study will include women undergoing IVF treatment with a GnRH antagonist protocol and fresh embryo transfer at the IVF unit of Shaare Zedek Medical Center. Patients will undergo controlled ovarian stimulation followed by ovulation triggering with hCG, GnRH agonist, or dual trigger according to OHSS risk. After oocyte retrieval and fertilization by IVF/ICSI, embryos will be cultured and transferred. Luteal phase support will consist of either intranasal GnRH agonist (Synarel) or vaginal progesterone. Blood and follicular fluid samples will be collected at predefined time points to assess hormonal, inflammatory, and angiogenic markers, including LH, FSH, estradiol, progesterone, IL-6, IL-8, VEGF, PEDF, and relaxin.
Official title: Gonadotropin-Releasing Hormone Agonist as a Single Luteal Support - What is Its Mechanism of Action?
Key Details
Gender
FEMALE
Age Range
18 Years - 45 Years
Study Type
OBSERVATIONAL
Enrollment
150
Start Date
2026-05-18
Completion Date
2026-12-31
Last Updated
2026-06-02
Healthy Volunteers
Yes
Conditions
Interventions
GnRH agonist
spray of 200 mcg Nafarelin (Synarel) twice a day for two weeks
Progesterone
PV progesterone administered until hCG day and continued for 8-10
Locations (1)
Shaare Zedek Medical Center
Jerusalem, Israel